Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent And Upcoming FDA Advisory Committee Meetings

Executive Summary

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

You may also be interested in...



Pediatric Testosterone Therapy: Sponsors Wary Of Trials Despite PREA

Studies are unfeasible, sponsors argue in advance of US advisory committee meeting that could lead to FDA ending its waiver on requiring clinical trials in pediatric patients for new testosterone replacement therapy products.

FTC ‘Organic’ Guidance Could Help To Curtail Litigation; Comments On 'Green Guides' Update Due 24 April

The US Federal Trade Commission is accepting comments through 24 April on potential updates to its Guides for the Use of Environmental Marketing Claims, aka “Green Guides,” including on whether it should address “organic” product advertising. Angela Diesch, a partner at law firm Amin Talati Wasserman, discusses.

Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents

Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel